Our story: Neuroreset
About a year back, we kept facing the same tough reality:
Neural recovery isn’t something you can just turn on like a switch.
It’s a system in which biology, psychology, and our environment work together.
This realization led us to develop NeuroReset™ at Biotech International Institute.
It’s not a “miracle product.”
It’s also not a clinical therapy.
But it is a research-driven framework and a patent-pending R&D project. Our goal is to see if a carefully designed molecular scaffold can help researchers map and eventually test new pathways involved in neural recovery.
The story behind the approach.
Most brain science solutions focus on just one target.
NeuroReset™ is being studied as a multi-pathway approach, since real recovery often involves several systems working together. We’re currently exploring:
Neurotransmitter signaling, including dopamine, glutamate, and serotonin, which we study for modulation in controlled experimental settings
Neural plasticity, looking at markers related to synaptic adaptability in preclinical models
Cue/stress reactivity, examining how response patterns to reward cues or stress signals might alter in non-clinical models
What it’s made of (conceptually).
NeuroReset™ is basically a bioengineered, semi-synthetic scaffold. Its design is inspired by cannabinoid analogs, indole structures found in psilocybin, and research on neurotrophic mushrooms.
After that, we focus on the less visible parts of innovation: synthesis, purification, confirming structure, mapping receptors, and running preclinical experiments. These steps are necessary before making any responsible claims.
A clear note on what we are (and aren’t) saying.
NeuroReset™ does not constitute a therapy, drug, or clinical product.
No claims are being made regarding safety, efficacy, or clinical benefits.
Why share this now?
Responsible innovation requires beginning with a hypothesis, followed by method development, data collection, critical evaluation, and only subsequently, consideration of real-world applications.
The team is open to substantive collaborations, including academic, translational, and non-clinical research partnerships. Such collaborations aim to clarify mechanisms, safety profiles, and future research directions.
Question for the neuroscience and recovery community:
If you could better “map” neural recovery, what would you prioritize first? Would you choose plasticity, stress reactivity, or multi-neurotransmitter signaling?
Share your thoughts in the comments. If you’re a research partner interested in working together, let’s connect.
NeuroReset™ article: https://www.biotechinternationalinstitute.com/neuroreset-article
Biotech International Institute: https://www.biotechinternationalinstitute.com/
